aqst stock forecast 2025
aqst stock forecast 2025
According to the latest forecasts, Aquestive Therapeutics (AQST) stock is expected to trade within a range of $2.57 to $3.25 in 2025. The average price for the year is projected to be around $2.82. Here are some key points:
Shortterm Outlook: In March 2025, AQST is expected to see a price drop of 7.77%, with an average price of $2.87. By April 2025, the price is forecasted to be around $2.68.
Longterm Outlook: For the full year of 2025, AQST's average price is expected to be $2.82, with a potential ROI of 4.47% compared to the current rates. However, another source suggests a more optimistic outlook, with a 1year price target of $11.40.
Revenue Forecast: Wall Street analysts forecast AQST's revenue for 2025 to be around $4.9 billion, with a decline of 14% compared to the previous year. However, the company's revenue growth rate is still expected to outperform the industry average.
Overall, AQST stock faces some nearterm challenges, but there is potential for growth in the long run. Investors should consider the volatility and the company's financial performance when making investment decisions.
Shortterm Outlook: In March 2025, AQST is expected to see a price drop of 7.77%, with an average price of $2.87. By April 2025, the price is forecasted to be around $2.68.
Longterm Outlook: For the full year of 2025, AQST's average price is expected to be $2.82, with a potential ROI of 4.47% compared to the current rates. However, another source suggests a more optimistic outlook, with a 1year price target of $11.40.
Revenue Forecast: Wall Street analysts forecast AQST's revenue for 2025 to be around $4.9 billion, with a decline of 14% compared to the previous year. However, the company's revenue growth rate is still expected to outperform the industry average.
Overall, AQST stock faces some nearterm challenges, but there is potential for growth in the long run. Investors should consider the volatility and the company's financial performance when making investment decisions.